title: Extra-amniotic balloon with PGE2 versus extra-ovular Foley catheter with PGF2alpha in mid-trimester pregnancy termination.
abstract: OBJECTIVE
  The objective of this study was to compare the efficacy and side effects of two methods of mid-trimester labor induction, extra-amniotic balloon with intracervical prostaglandin (PG) E2 (0.5 mg x 2) vs. extra-ovular Foley catheter with intrauterine PGF2alpha (1 mg/h x6).
  
  
  METHODS
  A cohort of 32 and 36 cases indicated for mid-trimester termination was enrolled and managed with extra-amniotic balloon and extra-ovular Foley catheter methods, respectively. Outcomes of induction-to-delivery interval, induction failure, and occurrence of side effects were assessed.
  
  
  RESULTS
  There were no statistical differences in maternal age, parity, gestational age or fetal birth weight between the two groups. Compared with the extra-ovular Foley catheter with PGF2alpha group, the induction-to-delivery interval was significantly shorter in the extra-amniotic balloon plus PGE2 group. There was no significant difference in side effects and major complications developed in either groups.
  
  
  CONCLUSIONS
  The extra-amniotic balloon with intracervical PGE2 is more efficient in reducing the induction-to-delivery interval for termination of mid-trimester pregnancies than the extra-ovular Foley catheter with intrauterine PGF2alpha.
authors.affiliation: Department of Obstetrics and Gynecology, Tri-Service General Hospital, Taipei, Taiwan.
authors.forename: H S
authors.initials: HS
authors.lastname: Liu
authors.forename: Y K
authors.initials: YK
authors.lastname: Chang
authors.forename: T Y
authors.initials: TY
authors.lastname: Chu
authors.forename: M H
authors.initials: MH
authors.lastname: Yu
authors.forename: W H
authors.initials: WH
authors.lastname: Chen
mesh_terms: D000028:Abortion, Induced / Q000295:instrumentation / Q000379:methods*; D000328:Adult; D000650:Amnion / Q000187:drug effects; D002404:Catheterization / Q000295:instrumentation / Q000379:methods*; D015331:Cohort Studies; D015237:Dinoprost / Q000008:administration & dosage*; D015232:Dinoprostone / Q000008:administration & dosage*; D005260:Female; D005865:Gestational Age; D006801:Humans; D015552:Injections, Intralesional; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D016896:Treatment Outcome
chemical_list: D015237:Dinoprost; D015232:Dinoprostone